无线电技术
医学
比例危险模型
接收机工作特性
肿瘤科
内科学
生物标志物
Lasso(编程语言)
相关性
放化疗
生存分析
放射治疗
放射科
生物
计算机科学
万维网
生物化学
数学
几何学
作者
Congying Xie,Pengfei Yang,Xuebang Zhang,Lei Xu,Xiaoju Wang,Xiadong Li,Luhan Zhang,Ruifei Xie,Ling Yang,Jing Zhao,Hongfang Zhang,Lingyu Ding,Yu Kuang,Tianye Niu,Shixiu Wu
出处
期刊:EBioMedicine
[Elsevier]
日期:2019-06-01
卷期号:44: 289-297
被引量:80
标识
DOI:10.1016/j.ebiom.2019.05.023
摘要
BackgroundEvaluating clinical outcome prior to concurrent chemoradiotherapy remains challenging for oesophageal squamous cell carcinoma (OSCC) as traditional prognostic markers are assessed at the completion of treatment. Herein, we investigated the potential of using sub-region radiomics as a novel tumour biomarker in predicting overall survival of OSCC patients treated by concurrent chemoradiotherapy.MethodsIndependent patient cohorts from two hospitals were included for training (n = 87) and validation (n = 46). Radiomics features were extracted from sub-regions clustered from patients' tumour regions using K-means method. The LASSO regression for ‘Cox’ method was used for feature selection. The survival prediction model was constructed based on the sub-region radiomics features using the Cox proportional hazards model. The clinical and biological significance of radiomics features were assessed by correlation analysis of clinical characteristics and copy number alterations(CNAs) in the validation dataset.FindingsThe overall survival prediction model combining with seven sub-regional radiomics features was constructed. The C-indexes of the proposed model were 0.729 (0.656–0.801, 95% CI) and 0.705 (0.628–0.782, 95%CI) in the training and validation cohorts, respectively. The 3-year survival receiver operating characteristic (ROC) curve showed an area under the ROC curve of 0.811 (0.670–0.952, 95%CI) in training and 0.805 (0.638–0.973, 95%CI) in validation. The correlation analysis showed a significant correlation between radiomics features and CNAs.InterpretationThe proposed sub-regional radiomics model could predict the overall survival risk for patients with OSCC treated by definitive concurrent chemoradiotherapy.FundThis work was supported by the Zhejiang Provincial Foundation for Natural Sciences, National Natural Science Foundation of China.
科研通智能强力驱动
Strongly Powered by AbleSci AI